Hansa Biopharma AB (LTS:0RC7) Notes Receivable: kr0.0 Mil (As of Mar. 2026)


LTS:0RC7 Hansa Biopharma AB LTS:0RC7
63 GF Score
Price kr34.48
GF Value kr24.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Notes Receivable?

Hansa Biopharma AB LTS:0RC7 -1.63% 63 Notes Receivable is kr0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0RC7 with a GF Score™ of 63/100 and a GF Value™ of kr24.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Hansa Biopharma AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.0 Mil.

Hansa Biopharma AB Notes Receivable Related Terms

Hansa Biopharma AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Notes Receivable Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0RC7
63GF Score
Hansa Biopharma AB LTS:0RC7
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.0 Mil mean?
Hansa Biopharma AB (LTS:0RC7) has a Notes Receivable of kr0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Notes Receivable too high?
Hansa Biopharma AB's current Notes Receivable is kr0.0 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Notes Receivable compare to VRTX and REGN?
Hansa Biopharma AB's Notes Receivable of kr0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Notes Receivable is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (LTS:0RC7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.57, compared to a current price of kr34.48 — trading 40.3% above its estimated fair value. The current Notes Receivable is kr0.0 Mil. Hansa Biopharma AB's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Hansa Biopharma AB (LTS:0RC7), the current Notes Receivable is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (LTS:0RC7) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr34.48 is trading 40.3% above its estimated GF Value™ of kr24.57. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for LTS:0RC7:

  • Notes Receivable: kr0.0 Mil
  • GF Value™: kr24.57 vs. price of kr34.48 (40.3% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the LTS:0RC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
63GF Score

Get the complete analysis for LTS:0RC7

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.48
Price
kr24.57
GF Value